112.13MMarket Cap
LossP/E TTM
Key Figures
1.050Open
1.075High
478.64KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.45%Turnover Ratio
1.050Prev. Close
1.005Low
297.56KTurnover
LossP/E Static
0.65P/B
0.00%Div Yield TTM
-18.43%ROA
2.40052wk High
0.53Volume Ratio
-41.05MNet Profit
106.79MShares
-0.3669EPS TTM
1.45Beta
-21.30%ROE
0.64352wk Low
6.67%Amplitude
73.22%Gross Margin
112.13MMarket Cap
-4.16Reward/Risk
4.17%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
MaxCyte Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 70 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.11.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance

Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
MaxCyte Inc Highlights
StrengthsRisks
MaxCyte Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Intuitive Surgical Inc
ISRG
35
Boston Scientific Corp
BSX
34
Edwards Lifesciences Corp
EW
33
Thermo Fisher Scientific Inc
TMO
30
Indicators
Financial Indicators
EPS

Relevant data have not been disclosed by the company yet.
Total revenue

Relevant data have not been disclosed by the company yet.
MaxCyte Inc Info
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Ticker SymbolMXCT
CompanyMaxCyte Inc
CEOMasoud (Maher)
Websitehttps://www.maxcyte.com/
Shareholders
FAQs
What is the current price of MaxCyte Inc (MXCT)?
The current price of MaxCyte Inc (MXCT) is 1.05.
What is the symbol of MaxCyte Inc?
The ticker symbol of MaxCyte Inc is MXCT.
What is the 52-week high of MaxCyte Inc?
The 52-week high of MaxCyte Inc is 2.40.
What is the 52-week low of MaxCyte Inc?
The 52-week low of MaxCyte Inc is 0.64.
What is the market capitalization of MaxCyte Inc?
The market capitalization of MaxCyte Inc is 112.13M.
Is MaxCyte Inc (MXCT) currently rated as Buy, Hold, or Sell?
According to analysts, MaxCyte Inc (MXCT) has an overall rating of Buy, with a price target of 4.11.
What is the Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT)?
The Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT) is -0.42.